Both men and women with psoriasis are equally at risk for developing psoriatic arthritis (PsA)—a chronic inflammatory ...

The FDA has accepted for review the sNDA for deucravacitinib for the treatment of adults with active psoriatic arthritis.

Tildrakizumab is an interleukin-23 antagonist approved under the brand name Ilumya for the treatment of plaque psoriasis.

Understand how psoriatic arthritis increases heart disease risk through inflammation. Learn management tips for heart health, from lifestyle changes to medication discussions.

Lyme disease is a complex condition with a long history of misdiagnosis, and Lyme arthritis, a late manifestation of the ...